Ecteinascidin synthetic analogues: a new class of selective inhibitors of transcription, exerting immunogenic cell death in refractory malignant pleural mesothelioma
Collectively, these findings reveal a previously unknown mechanism of action of ecteinascidins that merits further investigation for potential clinical applications in the treatment of MPM, as new first line treatment in monotherapy or in association with immunotherapy.
Authors
- Silvia Novello (ORCID: https://orcid.org/0000-0001-7653-9748)
- Francesca Napoli (ORCID: https://orcid.org/0000-0002-9745-998X)
- Chiara Riganti (ORCID: https://orcid.org/0000-0001-9787-4836)
- Alessandra Merlini (ORCID: https://orcid.org/0000-0002-5280-1411)
- Luisella Righi (ORCID: https://orcid.org/0000-0002-8927-204X)
- Iris C. Salaroglio (ORCID: https://orcid.org/0000-0002-6043-3794)
- Pablo Avilés (ORCID: https://orcid.org/0000-0003-0414-5365)
- Joanna Kopecka (ORCID: https://orcid.org/0000-0003-3612-3953)
- Harold C. Sullivan (ORCID: https://orcid.org/0000-0003-4909-7168)
- Giorgio V. Scagliotti (ORCID: https://orcid.org/0000-0001-6646-958X)
Institutions
- PharmaMar (Spain) (ES)
- Ospedale San Luigi Gonzaga (IT)
- University of Turin (IT)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1186/s13046-024-03253-y
- Citations
- 4
- Primary Topic
- Occupational and environmental lung diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Associazione Italiana per la Ricerca sul Cancro